Home
Products
Customized ADCs
ERBB2
Anti-HER2-MODO ADC

Anti-HER2-MODO ADC (CAT#: ADC-W-212)

Name: Anti-HER2-MODO ADC
SKU: ADC-W-212
Rating: 5 (1 reviews)

This ADC product is comprised of an anti-ERBB2 monoclonal antibody conjugated via a linker to MODO. The MODO is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MODO binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

ADC Target
ADC Antibody
ADC payload drug

Name
ERBB2

Alternative Names
ERBB2; erb-b2 receptor tyrosine kinase 2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; receptor tyrosine-protein kinase erbB-2; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2; metastatic lymph node gene 1

Target Entrez Gene ID
2064

Target UniProt ID
P04626

Overview
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.

Overview
Humanized Anti-ERBB2 lgG1 antibody

Species Reactivity
Human

Name
MODO (monomethyldolastatin)

Description
Dolastatin is originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity. Binding to tubulin, dolastatin 10 inhibits microtubule assembly, resulting in the formation of tubulin aggregates and inhibition of mitosis. This agent also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-212. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Payload

CAT#	Product Name	Linker	Payload
ADC-W-1113	Anti-ERBB2 (Pertuzumab)-SPDB-DM4 ADC	SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate)	DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-1116	Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-SN38 ADC	MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)	SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-1111	Anti-ERBB2 (Margetuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC	MC-Vc-PAB-DMEA-(PEG2)	duocarmycin SA
ADC-W-2596	Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-SN38 ADC	MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)	SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-116	Anti-ERBB2 (Trastuzumab)-Gly5-modified DM1 ADC	C-terminal GS (glycine-serine) linker	Gly5-modified DM1 (Gly5-modified N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-W-211	Anti-EGFR (Cetuximab)-VC-PAB-MODO ADC	VC-PAB (valine-citrulline-p-aminobenzoyloxycarbonyl)	MODO (monomethyldolastatin)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.